MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.37% | 46.28% | 19.27% | 26.62% | 32.77% |
| Total Depreciation and Amortization | -34.53% | -22.85% | 1.95% | 16.82% | 13.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.07% | 133.35% | 130.29% | 157.53% | 143.20% |
| Change in Net Operating Assets | -129.18% | -162.38% | -52.65% | -7.69% | -30.31% |
| Cash from Operations | -47.24% | 43.94% | 61.32% | 83.57% | 64.39% |
| Capital Expenditure | 65.87% | 63.73% | 67.94% | 65.66% | 37.24% |
| Sale of Property, Plant, and Equipment | 55.75% | -99.22% | -72.88% | -61.16% | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -100.00% |
| Divestitures | -- | -- | -- | -29.51% | -29.51% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -37.90% | -102.01% | -93.93% | -42.65% | 2.34% |
| Total Debt Issued | -26.57% | -25.12% | -25.12% | -25.12% | -29.80% |
| Total Debt Repaid | -147.96% | -63.38% | -51.72% | -43.88% | 41.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -64.97% | -80.98% | -32.12% | -18.23% | -12.95% |
| Cash from Financing | -3,250.97% | -498.90% | -405.53% | -252.49% | 119.04% |
| Foreign Exchange rate Adjustments | 106.52% | 102.60% | 101.58% | -73.61% | -179.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -546.65% | -148.24% | 0.53% | 102.19% | 116.39% |